Harrison’s Biotech Stocks at the end of Q1.
IBRX (ImmunityBio) PDUFA date is April 23rd. Hoping for FDA approval of ImmunityBio’s bladder cancer drug, Anktiva. If approved, the company will go it alone or partner with Big Pharma. I don’t think a buyout is in the cards, but would gladly be proven wrong. 27,800 shares at avg cost of $9.77
GERN (Geron) AdCom voted 12-2 to recommend the approval of GERN’s drug, Imetelstat, to the FDA. PDUFA date is June 16th. If approved, I believe there will be a buyout. Having said that, GERN had $375,000 in cash as of December 31st and has indicated a willingness to go it alone. But, IMO, they will, in time, be bought. MDS is a large indication and will be too tempting for Big Pharma. 6,000 shares at avg cost of $3.19. *Have been holding this since 2013 & good shit needs to happen.
RVPH (Reviva Pharmaceuticals) Phase 3 of their drug for schizophrenia, Brilaroxazine, is to be completed in Q4 of this year. I think Big Pharma partners with them before FDA approval in 2025. 15,000 shares at avg cost of $6.87.